Skip to main content
SpringerLink
Log in

Principles of Integrating Opioid Use Disorder Treatment in Primary Care

  • Chapter
  • First Online:
Treating Opioid Use Disorder in General Medical Settings

  • 461 Accesses

Abstract

Integration of opioid use disorder (OUD) treatment in primary care is crucial for expanding access to care. The availability of medications for OUD – in particular, buprenorphine – is the starting point for OUD treatment. Multidisciplinary treatment teams that consist of waivered primary care providers and care coordinators are common to integration. Initial assessments are anchored in confirming a diagnosis of OUD, determining patient readiness and goals for treatment, and planning for the care of comorbid conditions. Polysubstance use is not a contraindication to OUD treatment in primary care. Sublingual buprenorphine, the most widely used medication for OUD in primary care, can be safely initiated in patients using unobserved treatment initiation strategies. Maintaining patients in OUD treatment entails modifying or intensifying treatment according to patient needs. Additional psychosocial counseling beyond the scope of primary care–based OUD treatment should be offered but not required. Finally, a patient-centered approach to utilizing toxicology tests and addressing diversion is essential to integrating OUD treatment in primary care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health; 2019.

    Google Scholar 

  2. Barry CL, Epstein AJ, Fiellin DA, Fraenkel L, Busch SH. Estimating demand for primary care-based treatment for substance and alcohol use disorders. Addiction [Internet]. 2016;111(8):1376–84. Available from: http://doi.wiley.com/10.1111/add.13364.

    Article  Google Scholar 

  3. Wu L-T, McNeely J, Subramaniam GA, Brady KT, Sharma G, Van Veldhuisen P, et al. DSM-5 substance use disorders among adult primary care patients: results from a multisite study. Drug Alcohol Depend [Internet]. 2017;179(3):42–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0376871617303277.

    Article  Google Scholar 

  4. Lapham G, Boudreau DM, Johnson EA, Bobb JF, Matthews AG, McCormack J, et al. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug Alcohol Depend [Internet]. 2020;207(May 2019):107732. Available from: https://doi.org/10.1016/j.drugalcdep.2019.107732.

  5. McLellan AT, Starrels JL, Tai B, Gordon AJ, Brown R, Ghitza U, et al. Can substance use disorders be managed using the chronic care model? Review and recommendations from a NIDA Consensus Group. Public Health Rev [Internet]. 2014;35(2). Available from: http://www.ncbi.nlm.nih.gov/pubmed/26568649.

  6. HHS. Medication-assisted treatment models of care for opioid use disorder in primary care settings. Heal Hum Serv [Internet]. 2016;(28). Available from: http://effectivehealthcare.ahrq.gov/ehc/products/636/2225/opioid-use-disorder-draft-report-160513.pdf.

  7. Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, et al. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med. 2017;166(4):268–78.

    Article  PubMed  Google Scholar 

  8. Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: what actually works? A systematic review. PLoS One. 2017;12:1–40.

    Google Scholar 

  9. Wakeman SE, Rigotti NA, Chang Y, Herman GE, Erwin A, Regan S, et al. Effect of integrating substance use disorder treatment into primary care on inpatient and emergency department utilization. J Gen Intern Med [Internet]. 2019;34(6):871–7. Available from: http://link.springer.com/10.1007/s11606-018-4807-x.

    Article  Google Scholar 

  10. Green TC, Clarke J, Brinkley-Rubinstein L, BDL M, Alexander-Scott N, Boss R, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75:405–7.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Tanum L, Solli KK, Latif Z-H, Benth JŠ, Opheim A, Sharma-Haase K, et al. Effectiveness of injectable extended-release naltrexone vs Daily buprenorphine-naloxone for opioid dependence. JAMA Psychiatry [Internet]. 2017;74(12):1197. Available from: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2017.3206.

  12. Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet [Internet]. 2018;391(10118):309–18. Available from: https://linkinghub.elsevier.com/retrieve/pii/S014067361732812X.

  13. New York State Department of Health AIDS Institute. Clinical guidelines program – treatment of opioid use disorder [Internet]. 2019. Available from: https://www.hivguidelines.org/substance-use/oud/.

  14. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med [Internet]. 2018;1–10. Available from: http://annals.org/article.aspx?doi=10.7326/M17-3107.

  15. Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.

    Article  PubMed  Google Scholar 

  16. Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17:116–20.

    Article  PubMed  Google Scholar 

  17. Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat [Internet]. 2009;37(4):426–30. Available from: https://doi.org/10.1016/j.jsat.2009.05.003.

  18. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med [Internet]. 2007;5(2):146–50. Available from: http://www.annfammed.org/cgi/doi/10.1370/afm.665.

    Article  Google Scholar 

  19. Tannous BA, Teng J. Secreted blood reporters: insights and applications. Biotechnol Adv [Internet]. 2011;29(6):997–1003. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2840630&tool=pmcentrez&rendertype=abstract.

    Article  CAS  Google Scholar 

  20. Stein MD, Cloe P, Friedmann PD. Brief report: buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038–41.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kunins HV, Sohler NL, Giovanniello A, Thompson D, Cunningham CO. A buprenorphine education and training program for primary care residents: implementation and evaluation. Subst Abus. 2013;34(3):242–7.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Holt SR, Segar N, Cavallo DA, Tetrault JM. The addiction recovery clinic: a novel, primary-care-based approach to teaching addiction medicine. Acad Med. 2017;92(5):680–3.

    Article  PubMed  Google Scholar 

  23. Pytell JD, Buresh ME, Graddy R. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. Addict Sci Clin Pract [Internet]. 2019;14(1):1–7. Available from: https://doi.org/10.1186/s13722-019-0175-z.

  24. Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Heal [Internet]. 2019;35(1):113–21. Available from: http://doi.wiley.com/10.1111/jrh.12328.

    Article  Google Scholar 

  25. Molfenter T, Knudsen HK, Brown R, Jacobson N, Horst J, Van Etten M, et al. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. Implement Sci. 2017;12(1):1–9.

    Article  Google Scholar 

  26. LaBelle CT, Han SC, Bergeron A, Samet JH. Office-Based Opioid Treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers. J Subst Abuse Treat [Internet]. 2016;60:6–13. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0740547215001464.

  27. Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med [Internet]. 2011;171(5):425–31. Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinternmed.2010.541.

    Google Scholar 

  28. DiPaula BA, Menachery E. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. J Am Pharm Assoc. 2015;55:187–92.

    Article  Google Scholar 

  29. Watkins KE, Ober AJ, Lamp K, Lind M, Setodji C, Osilla KC, et al. Collaborative care for opioid and alcohol use disorders in primary care. JAMA Intern Med [Internet]. 2017;177(10):1480. Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2017.3947.

  30. Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013;131:127–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Oldfield BJ, Muñoz N, McGovern MP, Funaro M, Villanueva M, Tetrault JM, et al. Integration of care for HIV and opioid use disorder. AIDS [Internet]. 2019;33(5):873–84. Available from: http://journals.lww.com/00002030-201904010-00012.

    Article  Google Scholar 

  32. Brunet N, Moore DT, Lendvai Wischik D, Mattocks KM, Rosen MI. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abus. 2020:1–8.

    Google Scholar 

  33. Fiellin DA, Pantalon MV, Pakes JP, O’Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse [Internet]. 2002;28(2):231–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12014814.

  34. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O’Connor PG, et al. Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. N Engl J Med [Internet]. 2006;355(4):365–74. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa055255.

  35. Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O’Connor PG, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med [Internet]. 2013;126(1):74.e11–7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3621718&tool=pmcentrez&rendertype=abstract.

  36. Bassuk EL, Hanson J, Greene RN, Richard M, Laudet A. Peer-delivered recovery support services for addictions in the United States: a systematic review. J Subst Abuse Treat [Internet]. 2016;63:1–9. Available from: https://doi.org/10.1016/j.jsat.2016.01.003.

  37. McNicholas L, Consensus Panel Chair. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treat Improv Protoc [Internet]. 2004;40(04–3939):1–172. Available from: http://www.buprenorphine.samhsa.gov/Bup_Guidelines.pdf.

  38. Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med [Internet]. 2011;5(4):254–63. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01271255-201112000-00003.

    Article  CAS  Google Scholar 

  39. Sokol R, Albanese M, Chew A, Early J, Grossman E, Roll D, et al. Building a Group-Based Opioid Treatment (GBOT) blueprint: a qualitative study delineating GBOT implementation. Addict Sci Clin Pract [Internet]. 2019;14(1):1–17. Available from: https://doi.org/10.1186/s13722-019-0176-y.

  40. Sokol R, LaVertu AE, Morrill D, Albanese C, Schuman-Olivier Z. Group-based treatment of opioid use disorder with buprenorphine: a systematic review. J Subst Abuse Treat [Internet]. 2018;84:78–87. Available from: https://doi.org/10.1016/j.jsat.2017.11.003.

  41. Roll D, Spottswood M, Huang H. Using shared medical appointments to increase access to buprenorphine treatment. J Am Board Fam Med. 2015;28(5):676–7.

    Article  PubMed  Google Scholar 

  42. Doorley SL, Ho CJ, Echeverria E, Preston C, Ngo H, Kamal A, et al. Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic. Subst Abus. 2017;38(1):26–30.

    Article  PubMed  Google Scholar 

  43. Fox AD, Cunningham CO. Abstracts from the 2020 annual meeting of the Society of General Internal Medicine. J Gen Intern Med [Internet]. 2020; Available from: http://link.springer.com/10.1007/s11606-020-05890-3.

  44. Uscher-Pines L, Raja P, Mehrotra A, Huskamp HA. Health center implementation of telemedicine for opioid use disorders: a qualitative assessment of adopters and nonadopters. J Subst Abuse Treat [Internet]. 2020;115(April):108037. Available from: https://doi.org/10.1016/j.jsat.2020.108037.

  45. Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA. Treatment of opioid use disorder during COVID-19: experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat [Internet]. 2020;118(January):108124. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0740547220303809.

  46. Drake C, Yu J, Lurie N, Kraemer K, Polsky D, Chaiyachati KH. Policies to improve substance use disorder treatment with telehealth during the COVID-19 pandemic and beyond. J Addict Med. 2020;14(5):e139–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wang L, Weiss J, Ryan EB, Waldman J, Rubin S, Griffin JL. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. J Subst Abuse Treat [Internet]. 2021;124(December 2020):108272. Available from: https://doi.org/10.1016/j.jsat.2020.108272.

  48. Harris M, Johnson S, Mackin S, Saitz R, Walley AY, Taylor JL. Low barrier tele-buprenorphine in the time of COVID-19. J Addict Med [Internet]. 2020;Publish Ah(00):12–4. Available from: https://journals.lww.com/10.1097/ADM.0000000000000682.

  49. Tofighi B, Grazioli F, Bereket S, Grossman E, Aphinyanaphongs Y, Lee JD. Text message reminders for improving patient appointment adherence in an office-based buprenorphine program: a feasibility study. Am J Addict. 2017;26(6):581–6.

    Article  PubMed  Google Scholar 

  50. Cunningham CO, Giovanniello A, Sacajiu G, Li X, Brisbane M, Sohler NL. Inquiries about and initiation of buprenorphine treatment in an inner-city clinic. Subst Abus [Internet]. 2009;30(3):261–2. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2746741&tool=pmcentrez&rendertype=abstract.

    Article  Google Scholar 

  51. Rawson R, Cousins SJ, McCann M, Pearce R, Van Donsel A. Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system. J Subst Abuse Treat [Internet]. 2019;97(August 2018):84–90. Available from: https://doi.org/10.1016/j.jsat.2018.11.003.

  52. Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder. J Addict Med [Internet]. 2017;11(4):286–92. Available from: http://insights.ovid.com/crossref?an=01271255-201708000-00009.

    Article  Google Scholar 

  53. D’Onofrio G, Chawarski MC, O’Connor PG, Pantalon MV, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. J Gen Intern Med [Internet]. 2017;32(6):660–6. Available from: http://link.springer.com/10.1007/s11606-017-3993-2.

  54. D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA – J Am Med Assoc. 2015;313(16):1636–44.

    Article  Google Scholar 

  55. Naeger S, Mutter R, Ali MM, Mark T, Hughey L. Post-discharge treatment engagement among patients with an opioid-use disorder. J Subst Abuse Treat [Internet]. 2016;69:64–71. Available from: https://doi.org/10.1016/j.jsat.2016.07.004.

  56. Englander H, Weimer M, Solotaroff R, Nicolaidis C, Chan B, Velez C, et al. Planning and designing the improving addiction care team (IMPACT) for hospitalized adults with substance use disorder. J Hosp Med [Internet]. 2017;12(5):339–42. Available from: http://www.journalofhospitalmedicine.com/jhospmed/article/136504/hospital-medicine/planning-and-designing-improving-addiction-care-team.

    Article  Google Scholar 

  57. Trowbridge P, Weinstein ZM, Kerensky T, Roy P, Regan D, Samet JH, et al. Addiction consultation services – linking hospitalized patients to outpatient addiction treatment. J Subst Abuse Treat [Internet]. 2017;79:1–5. Available from: https://doi.org/10.1016/j.jsat.2017.05.007.

  58. Watkins KE, Ober AJ, Lamp K, Lind M, Diamant A, Osilla KC, et al. Implementing the chronic care model for opioid and alcohol use disorders in primary care. Prog Community Heal Partnerships Res Educ Action [Internet]. 2017;11(4):397–407. Available from: https://muse.jhu.edu/article/683610.

    Article  Google Scholar 

  59. Hunter SB, Ober AJ, McCullough CM, Storholm ED, Iyiewuare PO, Pham C, et al. Sustaining alcohol and opioid use disorder treatment in primary care: a mixed methods study. Implement Sci [Internet]. 2018;13(1):83. Available from: https://implementationscience.biomedcentral.com/articles/10.1186/s13012-018-0777-y.

  60. Cunningham CO, Lum PJ. Integrating buprenorphine treatment for opioid use disorder in primary care settings [Internet]. 2015. Available from: https://ciswh.org/bupmanual.

  61. American Society of Addiction Medicine. National practice guidelines for the use of medications in the treatment of addiction involving opioid use [Internet]. 2015. Available from: http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/national-practice-guideline.pdf.

  62. American Society of Addiction Medicine. National practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med [Internet]. 2020;14(2S):1–91. Available from: https://journals.lww.com/10.1097/ADM.0000000000000633.

    Article  Google Scholar 

  63. Simon CB, Tsui JI, Merrill JO, Adwell A, Tamru E, Klein JW. Linking patients with buprenorphine treatment in primary care: predictors of engagement. Drug Alcohol Depend [Internet]. 2017;181(September):58–62. Available from: https://doi.org/10.1016/j.drugalcdep.2017.09.017.

  64. McElrath K. Medication-assisted treatment for opioid addiction in the United States: critique and commentary. Subst Use Misuse [Internet]. 2018;53(2):334–43. Available from: https://www.tandfonline.com/doi/full/10.1080/10826084.2017.1342662.

    Article  Google Scholar 

  65. Bhatraju EP, Grossman E, Tofighi B, McNeely J, DiRocco D, Flannery M, et al. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract [Internet]. 2017;12(1):7. Available from: http://ascpjournal.biomedcentral.com/articles/10.1186/s13722-017-0072-2.

  66. Payne BE, Klein JW, Simon CB, James JR, Jackson SL, Merrill JO, et al. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program. Drug Alcohol Depend [Internet]. 2019;200(May):71–7. Available from: https://doi.org/10.1016/j.drugalcdep.2019.03.009.

  67. Cunningham CO, Giovanniello A, Kunins HV, Roose RJ, Fox AD, Sohler NL. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. Am J Addict [Internet]. 2013;22(4):352–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23795874.

  68. Fox AD, Sohler NL, Starrels JL, Ning Y, Giovanniello A, Cunningham CO. Pain is not associated with worse office-based buprenorphine treatment outcomes. Subst Abus [Internet]. 2012;33(4):361–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22989279.

  69. Weinstein ZM, Cheng DM, Quinn E, Hui D, Kim H, Gryczynski G, et al. Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine. Drug Alcohol Depend [Internet]. 2017;170:9–16. Available from: https://doi.org/10.1016/j.drugalcdep.2016.10.039.

  70. Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med [Internet]. 2009;24(2):226–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19089508.

  71. Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat [Internet]. 2011;40(4):349–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21310583.

  72. Gunderson EW, Wang X-Q, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav [Internet]. 2010;35(5):537–40. Available from: http://www.nature.com/articles/nrm2621.

    Article  Google Scholar 

  73. Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med [Internet]. 2008;23(9):1393–8. Available from: http://link.springer.com/10.1007/s11606-008-0686-x.

    Article  Google Scholar 

  74. Boston Medical Center, Office-Based Addiction Treatment Training and Assistance. buprenorphine community induction guide for patients [Internet]. Available from: https://www.bmcobat.org/resources/?category=4.

  75. Sohler NL, Li X, Kunins HV, Sacajiu G, Giovanniello A, Whitley S, et al. Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat [Internet]. 2010;38(2):153–9. Available from: https://doi.org/10.1016/j.jsat.2009.08.001.

  76. Becker WC, Frank JW, Edens EL. Switching from high-dose, long-term opioids to buprenorphine: a case series. Ann Intern Med. 2020;173(1):70–1.

    Article  PubMed  Google Scholar 

  77. Ghosh SM, Klaire S, Tanguay R, Manek M, Azar P. A review of novel methods to support the transition from methadone and other full agonist opioids to buprenorphine/naloxone sublingual in both community and acute care settings. Can J Addict. 2019;10(4):41–50.

    Article  Google Scholar 

  78. Brar R, Fairbairn N, Sutherland C, Nolan S. Use of a novel prescribing approach for the treatment of opioid use disorder: buprenorphine/naloxone micro-dosing – a case series. Drug Alcohol Rev. 2020;39(5):588–94.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ [Internet]. 2017;357:j1550. Available from: https://www.bmj.com/lookup/doi/10.1136/bmj.j1550.

  80. Weinstein LC, Iqbal Q, Cunningham A, Debates R, Landistratis G, Doggett P, et al. Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: Pennsylvania, 2017–2018. Am J Public Health [Internet]. 2020;110(4):580–6. Available from: https://doi.org/10.2105/AJPH.2019.305525.

  81. Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend [Internet]. 2013;131(1–2):127–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23332439.

  82. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis [Internet]. 2012;31(3):207–25. Available from: http://www.tandfonline.com/doi/abs/10.1080/10550887.2012.694598.

    Article  Google Scholar 

  83. Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.

    Article  PubMed  Google Scholar 

  84. Bozinoff N, Anderson BJ, Bailey GL, Stein MD. Correlates of stigma severity among persons seeking opioid detoxification. J Addict Med. 2018;12:19–23.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Fox AD, Masyukova M, Cunningham CO. Optimizing psychosocial support during office-based buprenorphine treatment in primary care: patients’ experiences and preferences. Subst Abus [Internet]. 2016;37(1):70–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801741/pdf/nihms-747268.pdf.

    Article  Google Scholar 

  86. Tetrault JM, Moore BA, Barry DT, O’Connor PG, Schottenfeld R, Fiellin DA, et al. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat [Internet]. 2012;43(4):433–9. Available from: https://doi.org/10.1016/j.jsat.2012.07.011.

  87. Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med [Internet]. 2016;10(2):93–103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26808307.

  88. Donroe JH, Holt SR, O’Connor PG, Sukumar N, Tetrault JM. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. Drug Alcohol Depend [Internet]. 2017;180(August):46–51. Available from: https://doi.org/10.1016/j.drugalcdep.2017.07.040.

  89. Starrels JL, Fox AD, Kunins HV, Cunningham CO. They don’t know what they don’t know: internal medicine residents’ knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med. 2012;27(11):1521–7.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Gaither JR, Gordon K, Crystal S, Edelman EJ, Kerns RD, Justice AC, et al. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug Alcohol Depend [Internet]. 2018;(May):0–1. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0376871618303855.

  91. Tenore PL. Advanced urine toxicology testing. J Addict Dis [Internet]. 2010;29(4):436–48. Available from: http://www.tandfonline.com/doi/abs/10.1080/10550887.2010.509277.

    Article  Google Scholar 

  92. Starrels JL, Wu B. Urine drug testing: a reference guide for clinicians. Bronx; 2013. https://ciswh.org/bupmanual.

  93. Accurso AJ, Lee JD, Mcneely J. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio. J Subst Abuse Treat [Internet]. 2017;83:62–7. Available from: https://doi.org/10.1016/j.jsat.2017.10.002.

  94. Holt SR, Donroe JH, Cavallo DA, Tetrault JM. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder. Drug Alcohol Depend [Internet]. 2018;186(October 2017):171–4. Available from: https://doi.org/10.1016/j.drugalcdep.2017.12.040.

  95. Netherland J, Botsko M, Egan JE, Saxon AJ, Cunningham CO, Finkelstein R, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat [Internet]. 2009;36(3):244–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18715741.

  96. Cunningham CO, Kunins H V., Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med [Internet]. 2007;22(9):1325–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17619934.

  97. Caviness CM, Anderson BJ, de Dios MA, Kurth M, Stein M. Prescription medication exchange patterns among methadone maintenance patients. Drug Alcohol Depend. 2013;127(1–3):232–8.

    Article  PubMed  Google Scholar 

  98. Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med [Internet]. 2014;8(5):315–26. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01271255-201409000-00004.

    Article  CAS  Google Scholar 

  99. Goldsworthy RC, Schwartz NC, Mayhorn CB. Beyond abuse and exposure: framing the impact of prescription-medication sharing. Am J Public Health. 2008;98(6):1115–21.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007;3(1551–7489 (Print)):302–8.

    Google Scholar 

  101. Paone D, Tuazon E, Stajic M, Sampson B, Allen B, Mantha S, et al. Buprenorphine infrequently found in fatal overdose in New York City. Drug Alcohol Depend [Internet]. 2015;155:298–301. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0376871615015987.

    Article  CAS  Google Scholar 

  102. Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. J Subst Abus Treat. 2015;48(1):112–6.

    Article  Google Scholar 

  103. Mitchell SG, Kelly S, Brown B, Reisinger HS, Peterson J, Ruhf A, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict [Internet]. 2009;18(5):346–55. Available from: http://doi.wiley.com/10.1080/10550490903077820.

    Article  Google Scholar 

  104. Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, Tsui JI. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addict Sci Clin Pract [Internet]. 2019;14(1):11. Available from: https://doi.org/10.1186/s13722-019-0139-3.

  105. Godersky ME, Klein JW, Merrill JO, Blalock KL, Saxon AJ, Samet JH, et al. Acceptability and feasibility of a mobile health application for video directly observed therapy of buprenorphine for opioid use disorders in an office-based setting. J Addict Med. 2020:14(4):319–25.

    Google Scholar 

  106. Tofighi B, Grossman E, Bereket S, Lee JD. Text message content preferences to improve buprenorphine maintenance treatment in primary care. J Addict Dis [Internet]. 2016;35(2):92–100. Available from: https://doi.org/10.1080/10550887.2015.1127716.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA

    Tiffany Lu & Chinazo Cunningham

Authors
  1. Tiffany Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chinazo Cunningham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tiffany Lu .

Editor information

Editors and Affiliations

  1. Department of Medicine, Massachusetts General Hospital, Charlestown, MA, USA

    Sarah E. Wakeman

  2. Brown University, The Miriam and Rhode Island Hospitals, Providence, RI, USA

    Josiah D. Rich

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lu, T., Cunningham, C. (2021). Principles of Integrating Opioid Use Disorder Treatment in Primary Care. In: Wakeman, S.E., Rich, J.D. (eds) Treating Opioid Use Disorder in General Medical Settings. Springer, Cham. https://doi.org/10.1007/978-3-030-80818-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-80818-1_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-80817-4

  • Online ISBN: 978-3-030-80818-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation